
Fuji Pharma Co Ltd
TSE:4554

Fuji Pharma Co Ltd
EPS (Diluted)
Fuji Pharma Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Fuji Pharma Co Ltd
TSE:4554
|
EPS (Diluted)
ÂĄ180
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
![]() |
Takeda Pharmaceutical Co Ltd
TSE:4502
|
EPS (Diluted)
ÂĄ131
|
CAGR 3-Years
-22%
|
CAGR 5-Years
73%
|
CAGR 10-Years
7%
|
|
![]() |
Daiichi Sankyo Co Ltd
TSE:4568
|
EPS (Diluted)
ÂĄ155
|
CAGR 3-Years
65%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-10%
|
|
![]() |
Otsuka Holdings Co Ltd
TSE:4578
|
EPS (Diluted)
ÂĄ633
|
CAGR 3-Years
40%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
![]() |
Chugai Pharmaceutical Co Ltd
TSE:4519
|
EPS (Diluted)
ÂĄ249
|
CAGR 3-Years
2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
24%
|
|
![]() |
Astellas Pharma Inc
TSE:4503
|
EPS (Diluted)
ÂĄ28
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
Fuji Pharma Co Ltd
Glance View
Fuji Pharma Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 1,532 full-time employees. The firm is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.

See Also
What is Fuji Pharma Co Ltd's EPS (Diluted)?
EPS (Diluted)
180.8
JPY
Based on the financial report for Dec 31, 2024, Fuji Pharma Co Ltd's EPS (Diluted) amounts to 180.8 JPY.
What is Fuji Pharma Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
11%
Over the last year, the EPS (Diluted) growth was -13%. The average annual EPS (Diluted) growth rates for Fuji Pharma Co Ltd have been 25% over the past three years , 17% over the past five years , and 11% over the past ten years .